samrotamab vedotin

**Samrotamab vedotin** is an antibody-drug conjugate (ADC) that consists of a monoclonal antibody targeting *leucine-rich repeat containing 15* (**LRRC15**) conjugated to the cytotoxic drug monomethyl auristatin E (**MMAE**). LRRC15 is a type I transmembrane protein that is overexpressed in several mesenchymal tumors, including sarcomas, as well as in cancer-associated fibroblasts, where it is associated with tumor growth, metastasis, and a suppressive tumor microenvironment. The MMAE payload induces cell death by inhibiting tubulin polymerization. Samrotamab vedotin was originally developed by AbbVie and investigated primarily for solid tumors—most notably sarcoma, glioblastoma, and melanoma. In phase 1 trials, it demonstrated safety and some activity in certain sarcoma subtypes but modest efficacy overall.

Other names

samrotamab vedotinABBV-085ABBV085ABBV 085